Trading SPY Options is Gone After Today?

Here's what you missed last week... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

SPONSORED The Small Biotech Scaring Big Pharma On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of genetic software that has the potential to eliminate genetic disease from our species. Bill Gates and Google Ventures have already invested $120 million into this, and Investor's Business Daily estimates the market is worth at least $75 billion. CLICK HERE to see how you can profit from this rare opportunity. >>>

– BREAKING –

Last week, we did something rare... We shared the lead article from this month's issue of Chief Income Strategist Marc Lichtenfeld's newsletter, The Oxford Income Letter. Typically, these articles are reserved for subscribers to The Oxford Income Letter, but we felt that this article had such valuable insights into Marc's current view of the market that it should be shared with everyone. Read this article to understand Marc's view on a recession in 2023...

– THE BIG REVEAL –

It's not often that Safety Net gets it wrong, especially when it comes to dividends it deems safe. Last year when we reviewed this company, it had plenty of cash flow, a low enough payout ratio and a solid history of annual dividend raises - everything Safety Net looks for in a dividend stock. But thanks to this company's declining cash flow and recent dividend cut, Marc is reevaluating its dividend safety. REVEAL THE GRADE

– THE VALUE METER –

On August 30, we received the biggest development in the United States' drug policy in 50 years. The U.S. Department of Health and Human Services has recommended marijuana be reclassified from a Schedule I substance to a Schedule III. This will move marijuana from being in the same category as heroin to the same category as Tylenol with codeine. The reclassification is massive news for cannabis multistate operators. In this Value Meter, Contributing Analyst Jody Chudley analyzes the cannabis industry and the best place to invest if you're looking for value. Jody reveals all in THIS article.

– OVERHEARD –

"[Wealthy Retirement has helped me] 1. increase diversification of my portfolio, 2. understand new investment strategies, and 3. make bond investing sensible at last." - Wealthy Retirement Reader Dr. J. Turner C. Have an experience that you'd like to share with the team at Wealthy Retirement? Click here to send us a message.

SPONSORED The Only Stock That Could ROCKET in Today's Market One company has taken the subscription model of streaming services and applied it to a surprising industry... One expert believes: "This Stock Under $3 Could Hit $20 in the Years Ahead..." WARNING: If you aren't in by November 2023 - your chance could be gone forever. View the Shocking Details Here

– TOP ARTICLE –

IS THIS THE PERFECT TIME TO BUY BONDS? Marc hasn't seen a better opportunity in the bond market in his 16 years with The Oxford Club. Yields are strong, and if a recession does occur, bonds that are bought today will be big winners, generating lots of income. Here's why Marc is so bullish on bonds...

– MORE FROM OUR NETWORK OF EXPERTS –

Will the Market Finish the Year Strong? >> How Woke Capitalism Costs You Money >> This Ratio Tells Us When to Buy Silver >>

Facebook LinkedIn

SPONSORED Bestselling Financial Author Warns: How to Protect Your Money From China's Evil Plot to Destroy America The man CNBC calls "the Market Maven," who has consulted with several of the world's billionaires and political leaders... Just issued a rare warning urging investors to immediately protect their money... Before China can fully execute their sinister plot to destroy America. Smart investors should watch this video NOW to receive all the important details on this looming crisis. [SEE THE URGENT DETAILS]

You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2023 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 877.808.9795 | International: +1.443.353.4621 Oxfordclub.com

Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.